Status of acute symptomatic attacks in a female patient with thyrotoxicosis: Hashimoto’s encephalopathy. Case report


如何引用文章

全文:

详细

Hashimoto’s Encephalopathy is an autoimmune disease associated with significant increase in titer of autoantibodies to thyroid peroxidase and thyroglobulin and characterized by inflammatory and degenerative brain disorders. We report a clinical case of recurrent status of acute symptomatic attacks in a female patient with Hashimoto’s encephalopathy.

作者简介

Yu. Tokareva

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

A. Kotov

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

编辑信件的主要联系方式.
Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

E. Semenova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

Yu. Eliseev

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

M. Romanova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

M. Alakova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

I. Misnikova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

I. Komerdus

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: alex-013@yandex.ru
俄罗斯联邦, Moscow

参考

  1. Аникина М.А., Муравьев О.Б., Сотников А.С., Левин О.С. Энцефалопатия Хашимото. Журн. неврол. и психиатр. 2012; 10 (2): 33–38.
  2. Филиппов П.П. Паранеопластические антигены и ранняя диагностика рака. Соросовский образоват. журн. 2000; 6 (9): 3–9.
  3. Шнайдер Н.А., Дмитренко Д.В., Дыхно Ю.А. Ежикова В.В. Проблемы диагностики паранеопластического лимбического энцефалита. Журн. Эпилепсия и пароксизмальные состояния. 2013; 3 (5): 49–58.
  4. Anand K.S, Garg J., Verma R., Chakraborty A. Hashimoto’s Encephalitis:Unusual Cause of Reversible Dementia. J Family Med Prim Care 2014; 3 (3): 284–286. doi: 10.4103/2249-4863.141650. PMID: 25374873.
  5. Bismilla Z., Sell E., Donner E. Hashimoto encephalopathy responding to risperidone. J Child Neurol. 2007; 22: 855. doi: 10.1177/0883073807304202. PMID: 17715278.
  6. Blanchin S., Coffin C., Viader F. et al. Anti-thyroperoxidase antibodies from patients with Hashimoto’s encephalopathy bind to cerebellar astrocytes. J Neuroimmunol. 2007; 192: 13–20. doi: 10.1016/j.jneuroim.2007.08.012. PMID: 17963848.
  7. Brain L., Jellinek E.H., Ball К. Hashimoto’s disease and encephalopathy; Lancet 1966; 2: 512–514. doi: 10.1016/S0140-6736(66)92876-5. PMID: 4161638.
  8. Buckley C., Oger J., Clover L. et al. Potassium channel antibodies in two 25 patients with reversible limbic encephalitis. Ann. Neurol. 2001; 50: 73–78. doi: 10.1002/ana.1097. PMID: 11456313.
  9. Castillo P., Woodruff B., Caselli R. et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63: 197–202. doi: 10.1001/archneur.63.2.197. PMID: 16476807.
  10. De Holanda N.C., de Lima D.D., Cavalcanti T.B. et al. Hashimoto’s encephalopathy: systematic review of the literature and an additional case. J Neuropsychiatry Clin Neurosci. 2011; 23 (4): 384–390. doi: 10.1176/jnp.23.4.jnp384. PMID: 22231308.
  11. Ferracci F., Bertiato G., Moretto G. Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci. 2004; 217(2): 165–168. doi: 10.1016/j.jns.2003.09.007. PMID: 14706219.
  12. Fujii A., Yoneda M., Ito T. et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J Neuroimmunol. 2005; 162: 130–136. doi: 10.1016/j.jneuroim.2005.02.004. PMID: 15833368.
  13. Gliebus G., Lippa C.F. Cerebrospinal immunoglobulin level changes and clinical response to treatment of Hashimoto’s encephalopathy. Am J Alzheimer’s Dis Other Demen. 2009; 24 (5): 373–376. doi: 10.1177/1533317509339162. PMID: 19561326.
  14. Henchey R., Cibula J., Helveston W. et al. Electroencephalographic findings in Hashimoto’s encephalopathy. Neurology 1995; 45: 977–981.doi: 10.1212/WNL.45.5.977. PMID: 7746418.
  15. Irani S.R., Bera K., Waters P. et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133 (6): 1655–1667. doi: 10.1093/brain/awq113. PMID: 20511282.
  16. Dalmau J., Gleichman A.J., Hughes E.J. et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. The Lancet Neurology 2008; 7 (12): 1091–1098. doi: 10.1016/S1474-4422(08)70224-2. PMID: 18851928.
  17. Kothbauer-Margreiter I., Sturzenegger M., Komor J. et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996; 243: 585–593. doi: 10.1007/BF00900946. PMID: 8865025.
  18. Lalani N., Haq R. Prognostic effect of early treatment of paraneoplastic limbic encephalitis in a patient with small-cell lung cancer. Curr. Oncol. 2012; 19: 353–357. doi: 10.3747/co.19.1007. PMID: 23144583.
  19. Marshall G.A., Doyle J. Long-term treatment of Hashimoto’s encephalopathy. The Journal of Neuropsychiatry and Clinical Neurosciences 2006; 18: 14–20. doi: 10.1176/jnp.18.1.14. PMID: 16525066.
  20. Martin Т., Torres A., Gentil A. et al. Role of brain single photon emission computed tomography in the diagnosis of distinct forms of presentation of Hashimoto’s encephalopathy. Endocrinol Nutr. 2009; 56 (6): 344–347. doi: 10.1016/S1575-0922(09)71950-3. PMID: 19695517.
  21. Nieuwenhuis L., Santens P., Vanwalleghem P., Boon P. Subacute Hashimoto’s encephalopathy, treated with plasmapheresis. Acta Neurol Belg. 2004; 104: 80–83. PMID: 15508271.
  22. Prüss H., Dalmau J., Harms L. et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010; 75 (19): 1735–1739. doi: 10.1212/WNL.0b013e3181fc2a06. PMID: 21060097.
  23. Sapkota S.K., Sapkota B.L., Pitiyanuvath N. Hashimoto Encephalopathy or Neurosarcoidosis? A Case Report. Neurohospitalist 2015; 5(2): 70–73. doi: 10.1177/1941874414554299. PMID: 25829987.
  24. Song Y.M., Seo D.W., Chang G.Y. MR findings in Hashimoto encephalopathy. AJNR Am J Neuroradiol. 2004; 25: 807–808. PMID: 15140725.
  25. Titulaer M.J., McCracken L., Gabilondo I. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. The Lancet Neurology 2013; 12 (2): 157–165. doi: 10.1016/S1474 4422(12)70310-1. PMID: 23290630.
  26. Tsai M.H., Lee L.H., Chen S.D. et al. Complex partial status epilepticus as a manifestation of Hashimoto’s encephalopathy. Seizure 2007; 16: 713–716. doi: 10.1016/j.seizure.2007.05.018. PMID: 17600734.
  27. Watemberg N., Greenstein D., Levine A. Encephalopathy associated with Hashimoto thyroiditis: pediatric perspective. J Child Neurol. 2006; 21: 1–9. PMID: 16551444.
  28. Wong L.C., Freeburg J.D., Montouris G.D., Hohler A.D. Two patients with Hashimoto’s encephalopathy and uncontrolled diabetes successfully treated with levetiracetam. J Neurol Sci. 2015; 348 (1–2): 251–252. doi: 10.1016/j.jns.2014.11.007. PMID: 25467138.
  29. Yoneda M., Fujii A., Ito A. et al. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto’s encephalopathy. J Neuroimmunol. 2007; 185: 195–200. doi: 10.1016/j.jneuroim.2007.01.018. PMID: 17335908.

版权所有 © Tokareva Y.V., Kotov A.S., Semenova E.I., Eliseev Y.V., Romanova M.V., Alakova M.A., Misnikova I.V., Komerdus I.V., 2016

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##